On Monday, February 13th, Teva Pharmaceutical TEVA will release its fourth quarter earnings results after the bell. The company is a Zacks Rank 4 (Sell), and have a Value, Growth, and Momentum score of C.
Dave will look at Teva Pharmaceutical past earnings, looks at what is currently going on with the company, and give us his thoughts on their upcoming earnings announcement.
Furthermore, Dave will uncover some potential options trades for investors looking to make a play on Teva Pharmaceutical ahead of earnings.
Teva Pharmaceutical in Focus
Teva Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Teva Pharmaceutical is expected to report earnings at $1.32 per share according to the Zacks Consensus Estimate. Last quarter they met earnings expectations at $1.28 per share. They have an average earnings surprise of 2.59%.
Teva Pharmaceutical Industries Limited Price, Consensus and EPS Surprise
Teva Pharmaceutical Industries Limited Price, Consensus and EPS Surprise | Teva Pharmaceutical Industries Limited Quote
Bottom Line
How should investors play Teva Pharmaceutical ahead of their earnings report? For insights on the best options trades, then tune in at 1:00pm tomorrow to see David’s thoughts.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research